Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Second Genome Scores A Deal With Janssen, A First In The Field Of Microbiome Therapeutics

This article was originally published in The Pink Sheet Daily

Executive Summary

Second Genome’s ulcerative colitis research alliance with Janssen Biotech is a first in the burgeoning microbiome therapeutics space, which may be transitioning from venture investment to commercial partnering. But is the deal an inflection point or a fluke?

Advertisement

Related Content

Big Pharma Embraces Microbiome Research; Partnering Poised To Follow
Deal Watch: Roche/Foundation Medicine Highlights Hyper Deal-Making During J.P. Morgan
Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine
Deal Watch: Auxilium Accepts Endo Buyout Rather Than Completing Purchase Of QLT Shell
Enterome Extends Its Microbiome Platform
Start-Up Quarterly Statistics, Q2 2013
FDA Approves Simponi For Ulcerative Colitis
Second Genome Inc.

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS075920

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel